Trial Profile

Expanded access study of isomyosamine in rare pediatric autoinflammatory disease

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isomyosamine (Primary)
Indications Autoimmune disorders; Rheumatoid arthritis; Thyroiditis
Focus Expanded access; Therapeutic Use

Most Recent Events

27 Jun 2025 New trial record
24 Jun 2025 According to a TNF Pharmaceuticals media release, company announced that it has formed a philanthropic collaboration with the DADA2 Foundation. Together, the parties are expected to initiate a Compassionate Use (Expanded Access) study evaluating TNF's lead candidate isomyosamine as a potential treatment

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com